The aggressive peripheral T-cell lymphomas: 2012 Update on diagnosis, risk stratification, and management
The aggressive peripheral T-cell lymphomas: 2012 Update on diagnosis, risk stratification, and management
复制标题
DOI：
10.1002/ajh.23144
复制
发表时间：
2012-05-01
影响因子：
12.8
通讯作者：
Armitage, James O.
中科院分区：
文献类型：
--
作者：
Armitage, James O.
背景：t细胞淋巴瘤约占淋巴细胞恶性肿瘤的10-15%。这些淋巴瘤的发病率因地域而异，在亚洲部分地区发病率最高。诊断：侵袭性外周t细胞淋巴瘤（PTCL）的诊断通常采用WHO分类。血液病理学家诊断侵袭性PTCL的可重复性能力低于侵袭性b细胞淋巴瘤，侵袭性PTCL的可重复性范围为72-97%。风险分层：侵袭性PTCL患者采用安娜堡分类法进行分期。尽管存在一些争议，但正电子发射断层扫描（PET）在侵袭性b细胞淋巴瘤中似乎是有用的。最常用的预后指数是国际预后指数。侵袭性PTCL的特定亚型是一个重要的危险因素，间变性大细胞淋巴瘤的生存率最高，尤其是间变性淋巴瘤激酶阳性亚型的年轻患者。风险适应治疗：间变性大细胞淋巴瘤是唯一对环磷酰胺、阿霉素、长春新碱、强的松（CHOP）样方案有良好反应的亚组。血管免疫母细胞t细胞淋巴瘤只有大约20%的患者有延长的无病生存期，但接受自体移植的年轻患者在缓解期似乎表现更好。ptcl - non - specified （NOS）不是一种疾病。含蒽环类药物的治疗结果令人失望，需要一种新的方法。NK/ t细胞淋巴瘤局限于鼻子和鼻窦似乎是最好的治疗放射治疗方案。肠病相关PTCL和肝脾PTCL是罕见的疾病，通常对治疗反应较差，尽管一些肠病相关PTCL患者似乎从强化治疗中受益。点。中华血液学杂志，32(4):559 - 559,2012。(C) 2012 Wiley期刊公司
Background: T-cell lymphomas make up approximately 10-15% of lymphoid malignancies. The frequency of these lymphomas varies geographically, with the highest incidence in parts of Asia.Diagnosis: The diagnosis of aggressive peripheral T-cell lymphoma (PTCL) is usually made using the WHO classification. The ability of hematopathologists to reproducibly diagnose aggressive PTCL is lower than for aggressive B-cell lymphomas, with a range of 72-97% for the aggressive PTCLs.Risk Stratification: Patients with aggressive PTCL are staged using the Ann Arbor Classification. Although somewhat controversial, positron emission tomography (PET) scans appear to be useful as they are in aggressive B-cell lymphomas. The most commonly used prognostic index is the International Prognostic Index. The specific subtype of aggressive PTCL is an important risk factor, with the best survival seen in anaplastic large-cell lymphoma-particularly young patients with the anaplastic lymphoma kinase positive subtype.Risk Adapted Therapy: Anaplastic large-cell lymphoma is the only subgroup to have a good response to a cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)-like regimen. Angioimmunoblastic T-cell lymphoma has a prolonged disease-free survival in only similar to 20% of patients, but younger patients who have an autotransplant in remission seem to do better. PTCL-not otherwise specified (NOS) is not one disease. Anthracycline containing regimens have disappointing results and a new approach is needed. NK/T-cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy containing regimens. Enteropathy associated PTCL and hepatosplenic PTCL are rare disorders with a generally poor response to therapy, although selected patients with enteropathy associated PTCL seem to benefit from intensive therapy. Am. J. Hematol. 87:512-519, 2012. (C) 2012 Wiley Periodicals, Inc.